Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors: Systematic Review

Vardan Nersesjan, Oskar McWilliam, Lars-Henrik Krarup, View ORCID ProfileDaniel Kondziella
doi: https://doi.org/10.1101/2020.08.31.20185009
Vardan Nersesjan
1Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oskar McWilliam
1Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars-Henrik Krarup
1Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Kondziella
1Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
2Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel Kondziella
  • For correspondence: daniel_kondziella@yahoo.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

BACKGROUND Immune checkpoint inhibitors (ICPI) are a game changer in the treatment of various metastasized cancers, but emerging reports of adverse events, including ICPI-associated autoimmune encephalitis (ICPI-AIE), are concerning. We aimed to collect all published cases of ICPI-AIE to identify the salient clinical and laboratory features of this disorder.

METHODS We searched PubMed, The Cochrane Library and Embase for ICPI-AIE cases from the first description in 2015 until 01/2020 using standard bibliographic measures including PRISMA guidelines and pre-registration with PROSPERO (CRD42019139838).

RESULTS Thirty-nine studies met inclusion criteria, resulting in 54 ICPI-AIE patients (mean age 58.6 years; 43% females). Common cancers included melanoma (30%) and non-small cell lung cancer (30%). Brain metastases were found in 16 patients (30%). The most frequent ICPI was nivolumab (61%). Onset of ICPI-AIE occurred on average after 3.5 treatment cycles, but very early and late presentations were common. Non-limbic AIE was roughly twice as frequent as limbic AIE (p<0.05). The most common laboratory abnormalities included bitemporal FLAIR lesions on MRI, continuous slow waves and diffuse slowing on EEG, and monocytic pleocytosis on cerebrospinal fluid analysis. Of note, intraneuronal antibodies were more frequent than neuronal surface antibodies, and logistic regression identified the presence of intracellular antibodies as a significant predictor for lack of improvement after 1st line immunotherapy (p<0.05).

CONCLUSIONS ICPI-AIE consists of a heterogenous group of conditions. Neurologists will likely encounter ICPI-AIE more often in the future, but important unresolved questions include the exact pathophysiological mechanisms, the epidemiology and the best treatment approaches associated with ICPI-AIE.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

None

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This is a systematic review, so no IRB required

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Not applicable - all relevant data are presented in the Tables and the main manuscript body

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted September 02, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors: Systematic Review
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors: Systematic Review
Vardan Nersesjan, Oskar McWilliam, Lars-Henrik Krarup, Daniel Kondziella
medRxiv 2020.08.31.20185009; doi: https://doi.org/10.1101/2020.08.31.20185009
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors: Systematic Review
Vardan Nersesjan, Oskar McWilliam, Lars-Henrik Krarup, Daniel Kondziella
medRxiv 2020.08.31.20185009; doi: https://doi.org/10.1101/2020.08.31.20185009

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (238)
  • Allergy and Immunology (520)
  • Anesthesia (124)
  • Cardiovascular Medicine (1417)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (582)
  • Epidemiology (10280)
  • Forensic Medicine (6)
  • Gastroenterology (527)
  • Genetic and Genomic Medicine (2621)
  • Geriatric Medicine (254)
  • Health Economics (496)
  • Health Informatics (1728)
  • Health Policy (788)
  • Health Systems and Quality Improvement (671)
  • Hematology (266)
  • HIV/AIDS (564)
  • Infectious Diseases (except HIV/AIDS) (12078)
  • Intensive Care and Critical Care Medicine (647)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (288)
  • Neurology (2451)
  • Nursing (144)
  • Nutrition (377)
  • Obstetrics and Gynecology (489)
  • Occupational and Environmental Health (566)
  • Oncology (1318)
  • Ophthalmology (400)
  • Orthopedics (145)
  • Otolaryngology (235)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (342)
  • Pediatrics (776)
  • Pharmacology and Therapeutics (329)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2393)
  • Public and Global Health (4995)
  • Radiology and Imaging (892)
  • Rehabilitation Medicine and Physical Therapy (523)
  • Respiratory Medicine (681)
  • Rheumatology (309)
  • Sexual and Reproductive Health (254)
  • Sports Medicine (244)
  • Surgery (297)
  • Toxicology (45)
  • Transplantation (140)
  • Urology (108)